Hepatitis B Topics HBV Disease Progression Hepatitis Delta (HDV)
AASLD 2015: REP 2139 Shows Promise for People with Hepatitis B and Hepatitis Delta Coinfection
- Details
- Category: Experimental HBV Drugs
- Published on Sunday, 15 November 2015 00:00
- Written by Liz Highleyman
The nucleic acid-based polymer REP 2139, used first as monotherapy then combined with pegylated interferon, reduced hepatitis B surface antigen (HBsAg) levels, lowered hepatitis delta viral load, and increased anti-HBs antibody titers, according to findings from a small Phase 2 study presented at the AASLD Liver Meeting taking place this week in San Francisco. Participants fell into 2 distinct groups, with half being partial responders and half full responders.
EASL 2015: Prenylation Inhibitor Lonafarnib Lowers Hepatitis Delta Viral Load During Therapy
- Details
- Category: Hepatitis Delta (HDV)
- Published on Tuesday, 12 May 2015 00:00
- Written by Liz Highleyman
Lonafarnib, a farnesyl transferase inhibitor that interferes with viral assembly, reduced hepatitis delta virus (HDV) levels by more than 3 log in a Phase 2 study presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. Combining lonafarnib with pegylated interferon for 8 weeks led to significantly greater HDV RNA declines than lonafarnib alone, but boosting with ritonavir achieved an even greater effect with an all-oral regimen. HDV viral load rose again after stopping therapy, however, and researchers are now evaluating longer treatment durations.
Hepatitis Delta Found in 15% of HIV/HBV Coinfected People, Increases Risk of Death
- Details
- Category: Hepatitis Delta (HDV)
- Published on Thursday, 01 September 2011 00:00
- Written by Liz Highleyman
Approximately 15% of people with HIV who test positive for hepatitis B surface antigen (HBsAg) also carry hepatitis delta virus (HDV), a defective virus that can only replicate in the presence of hepatitis B virus (HBV) but can lead to more severe liver damage, according to a recent European study.
EASL 2015: Nucleic Acid Polymer REP 2139-Ca Shows Promise Against Hepatitis B and Delta Viruses
- Details
- Category: Experimental HBV Drugs
- Published on Monday, 11 May 2015 00:00
- Written by Liz Highleyman
The nucleic acid-based polymer REP 2139-Ca lowered hepatitis B surface antigen (HBsAg) levels and significantly reduced hepatitis B and hepatitis delta viral loads when combined with immunotherapy, according to presentations at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.
One-quarter of Patients Clear Hepatitis Delta with Pegylated Interferon
- Details
- Category: Hepatitis Delta (HDV)
- Published on Friday, 28 January 2011 03:30
- Written by HIVandHepatitis.com
Treatment with pegylated interferon (Pegasys) -- either alone or in combination with the antiviral drug adefovir (Hepsera) -- led to clearance of hepatitis delta virus (HDV) and improvement in liver enzyme levels, according to a small study published in the January 27, 2011, New England Journal of Medicine. Adefovir alone, however, had no effect on HDV.
EASL 2014: Prolonged Pegylated Interferon + Tenofovir Does Not Prevent Hepatitis Delta Relapse
- Details
- Category: Hepatitis Delta (HDV)
- Published on Friday, 18 April 2014 00:00
- Written by Liz Highleyman
Treating hepatitis B patients with hepatitis delta virus (HDV) coinfection using pegylated interferon plus tenofovir (Viread) for 96 weeks may reduce HDV viral load, but side effects are frequent and it did not significantly improve the likelihood of hepatitis B surface antigen (HBsAg) reduction, according to a report at the 49thEASL International Liver Congress last week in London.
Web Design and Development by